India Biotech to recruit 26,000 volunteers for third phase of Kovacin clinical trial

Advertisements
Advertisements

The recommendation for the India Biotech vaccine was made a day after the application for emergency use of the Oxford-AstraZeneca vaccine Covishield was approved by the Seram Institute of India.

Indigenous biotech company Bharat Biotech said on Saturday that it plans to achieve the goal of involving around 2,000 volunteers across the country for the third phase of clinical trials of the Covid-19 vaccine ‘Kovacsine’. The agency says 23,000 volunteers have already joined the test.

The agency said in a statement that an expert committee of the Central Medicine Authority of India had approved the use of Kovisin in case of emergency.

Advertisements

Read more: Government panel awaits final approval for India Biotech’s covid vaccine awaits final approval

The recommendation for the India Biotech vaccine was made a day after the application for emergency use of the Oxford-AstraZeneca vaccine Covishield was approved by the Seram Institute of India.

India Biotech, Serum Institute and Pfizer applied to the Drug Controller General of India (DCGI) for approval for emergency use of their respective vaccines.

Newsbip

Listen to the latest songs, only at JioSaavn.com

(This news is not edited by NDTV team. It is published directly from Syndicate feed))

Advertisements
India Biotech to recruit 26,000 volunteers for third phase of Kovacin clinical trial
India Biotech to recruit 26,000 volunteers for third phase of Kovacin clinical trial

We will be happy to hear your thoughts

Leave a Reply

NewsTree News - Latest News For You.
Logo